FIRST TRUST ALERIAN DISRUPTIVE TECHNOLOGY REAL ESTATE ETF DTRE 深 沪
等待开盘 02-20 09:30:00 美东时间
41.5192
+0.041
+0.10%
华盛通- 最 高41.5192
- 今 开41.4778
- 成交量 11股
- 最 低 41.5192
- 昨 收 41.4778
- 总市值 1625.93万
- 52周最高 42.10
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 33.1524
- 委 比 0.00%
- 总股本 39.16万
- 历史最高 49.8459
- 量 比 0.02
- 振 幅 0.00%
- 历史最低 16.6398
- 每 手 1
- 风险率 1.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Dec 3 (Reuters) - Windtree Therapeutics Inc WINT.PK: WINDTREE THERAPEUTICS ANNOUNCES IT HAS SIGNED A LETTER OF INTENT TO ACQUIRE COMMLOAN, INC. A REVENUE GENERATING COMPANY IN THE RAPIDLY GROWING FINT...
2025-12-03 22:03
BRIEF-Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Windtree Therapeutics Inc WINT.PK: WINDTREE THERAPEUTICS ANNOUNCES IT MAY RECEIVE LICENSE AGREEMENT PAYMENTS FROM ITS LICENSEE FOR RENEWED ACUTE PULMONARY DEVELOPMENT BY THE LICENSEE WINDTREE THERAPEU...
2025-11-17 22:09
BRIEF-Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Sept 2 (Reuters) - Windtree Therapeutics Inc WINT.PK: WINDTREE THERAPEUTICS STOCKHOLDERS APPROVE KEY PROPOSALS FOR REVENUE AND PROFIT GENERATION AT THE SPECIAL STOCKHOLDER MEETING Source text: ID:nGNX...
2025-09-03 00:52
BRIEF-Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study
Aug 5 (Reuters) - Windtree Therapeutics Inc WINT.O: WINDTREE THERAPEUTICS INC - ANNOUNCES INTERIM ANALYSIS OF ISTAROXIME PHASE 2 STUDY - SEC FILING WINDTREE THERAPEUTICS INC - ISTAROXIME ADDED TO INOT...
2025-08-05 21:50
BRIEF-Kraken And Windtree Therapeutics Announce Strategic Partnership For BNB Custody, Trading, And OTC Services
July 22 (Reuters) - Windtree Therapeutics Inc WINT.O: KRAKEN AND WINDTREE THERAPEUTICS ANNOUNCE STRATEGIC PARTNERSHIP FOR BNB CUSTODY, TRADING, AND OTC SERVICES WINDTREE THERAPEUTICS INC - TERM SHEET ...
2025-07-22 21:15
BRIEF-Windtree Therapeutics Enters Note Purchase Agreements On June 27, 2025
July 3 (Reuters) - Windtree Therapeutics Inc WINT.O: WINDTREE THERAPEUTICS INC - ENTERS NOTE PURCHASE AGREEMENTS ON JUNE 27, 2025 - SEC FILING ((Reuters.Briefs@thomsonreuters.com;))
2025-07-04 03:17
BRIEF-Windtree Announces Issuance Of Istaroxime Patent For The United States For Acute Heart Failure
July 2 (Reuters) - Windtree Therapeutics Inc WINT.O: WINDTREE ANNOUNCES ISSUANCE OF ISTAROXIME PATENT FOR THE UNITED STATES FOR ACUTE HEART FAILURE WINDTREE THERAPEUTICS INC - ISTAROXIME PATENT PROVID...
2025-07-02 21:05
BRIEF-Windtree Advances Lower Cost Manufacturing Of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel
June 26 (Reuters) - Windtree Therapeutics Inc WINT.O: WINDTREE ADVANCES LOWER COST MANUFACTURING OF PHEXXI, EVOFEM’S HORMONE-FREE, ON-DEMAND PRESCRIPTION CONTRACEPTIVE GEL WINDTREE THERAPEUTICS: CONTR...
2025-06-27 05:15
BRIEF-Windtree Therapeutics Inc - To Create Cryptocurrency Policy For Payments And Assets
Windtree Therapeutics Inc WINT.O: WINDTREE THERAPEUTICS INC - TO CREATE CRYPTOCURRENCY POLICY FOR PAYMENTS AND ASSETS WINDTREE THERAPEUTICS INC - IN DISCUSSIONS TO ACCEPT BITCOIN AND OTHER CRYPTOCURRE...
2025-06-04 04:24
BRIEF-Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
May 22 (Reuters) - Windtree Therapeutics Inc WINT.O: WINDTREE THERAPEUTICS ANNOUNCES ISTAROXIME CARDIOGENIC SHOCK SCAI STAGE C PHASE 2 STUDY PLANNED INTERIM ANALYSIS RESULTS TARGETED FOR JULY 2025 Sou...
2025-05-22 20:39
